Hyper-CVAD + Epratuzumab As a Salvage Regimen for Younger Patients with Relapsed/refractory CD22-positive Precursor B-cell Acute Lymphocytic Leukemia

Overview

Journal Haematologica

Specialty Hematology

Date 2017 Feb 4

PMID 28154086

Citations 2

Authors

Patrice Chevallier

Sylvain Chantepie

Francoise Huguet

Emmanuel Raffoux

Xavier Thomas

Thibaut Leguay

Tony Marchand

Francoise Isnard

Aude Charbonnier

Sebastien Maury

Maria-Pilar Gallego-Hernanz

Nelly Robillard

Thierry Guillaume

Pierre Peterlin

Alice Garnier

Fanny Rialland

Claire Le Houerou

David M Goldenberg

William A Wegener

Marie-C Bene

Herve Dombret

Affiliations

Soon will be listed here.

Citing Articles

Antibody-Based and Other Novel Agents in Adult B-Cell Acute Lymphoblastic Leukemia.

Csizmar C, Litzow M, Saliba A Cancers (Basel). 2025; 17(5).

PMID: 40075627 PMC: 11899621. DOI: 10.3390/cancers17050779.

The promise and perils of immunotherapy.

Lesch S, Gill S Blood Adv. 2021; 5(18):3709-3725.

PMID: 34581774 PMC: 8945582. DOI: 10.1182/bloodadvances.2021004453C.

Current Advances in Immunotherapy for Acute Leukemia: An Overview of Antibody, Chimeric Antigen Receptor, Immune Checkpoint, and Natural Killer.

Shang Y, Zhou F Front Oncol. 2019; 9:917.

PMID: 31616632 PMC: 6763689. DOI: 10.3389/fonc.2019.00917.

References

Advani A, McDonough S, Coutre S, Wood B, Radich J, Mims M . SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia. Br J Haematol. 2014; 165(4):504-9. PMC: 4209396. DOI: 10.1111/bjh.12778. View

Gokbuget N, Dombret H, Ribera J, Fielding A, Advani A, Bassan R . International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia. Haematologica. 2016; 101(12):1524-1533. PMC: 5479605. DOI: 10.3324/haematol.2016.144311. View

Maury S, Chevret S, Thomas X, Heim D, Leguay T, Huguet F . Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia. N Engl J Med. 2016; 375(11):1044-53. DOI: 10.1056/NEJMoa1605085. View

Chevallier P, Eugene T, Robillard N, Isnard F, Nicolini F, Escoffre-Barbe M . (90)Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: a phase 1 dose-escalation study. Lancet Haematol. 2015; 2(3):e108-17. DOI: 10.1016/S2352-3026(15)00020-4. View

Cortes J, Kim D, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C . A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013; 369(19):1783-96. PMC: 3886799. DOI: 10.1056/NEJMoa1306494. View

Chevallier P, Huguet F, Raffoux E, Etienne A, Leguay T, Isnard F . Vincristine, dexamethasone and epratuzumab for older relapsed/refractory CD22+ B-acute lymphoblastic leukemia patients: a phase II study. Haematologica. 2015; 100(4):e128-31. PMC: 4380733. DOI: 10.3324/haematol.2014.120220. View

Kantarjian H, DeAngelo D, Stelljes M, Martinelli G, Liedtke M, Stock W . Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. N Engl J Med. 2016; 375(8):740-53. PMC: 5594743. DOI: 10.1056/NEJMoa1509277. View

Koller C, Kantarjian H, Thomas D, OBrien S, Rios M, Kornblau S . The hyper-CVAD regimen improves outcome in relapsed acute lymphoblastic leukemia. Leukemia. 1998; 11(12):2039-44. DOI: 10.1038/sj.leu.2400861. View

Jabbour E, Short N, Jorgensen J, Yilmaz M, Ravandi F, Wang S . Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia. Cancer. 2016; 123(2):294-302. PMC: 5321541. DOI: 10.1002/cncr.30264. View

10.

Frey N, Luger S . How I treat adults with relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia. Blood. 2015; 126(5):589-96. DOI: 10.1182/blood-2014-09-551937. View

11.

Raetz E, Cairo M, Borowitz M, Blaney S, Krailo M, Leil T . Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study. J Clin Oncol. 2008; 26(22):3756-62. PMC: 2654811. DOI: 10.1200/JCO.2007.15.3528. View

12.

Faderl S, Thomas D, OBrien S, Ravandi F, Garcia-Manero G, Borthakur G . Augmented hyper-CVAD based on dose-intensified vincristine, dexamethasone, and asparaginase in adult acute lymphoblastic leukemia salvage therapy. Clin Lymphoma Myeloma Leuk. 2011; 11(1):54-9. DOI: 10.3816/CLML.2011.n.007. View

13.

Carnahan J, Wang P, Kendall R, Chen C, Hu S, Boone T . Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties. Clin Cancer Res. 2003; 9(10 Pt 2):3982S-90S. View

14.

Raetz E, Cairo M, Borowitz M, Lu X, Devidas M, Reid J . Re-induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): Phase II results from Children's Oncology Group (COG) study ADVL04P2. Pediatr Blood Cancer. 2015; 62(7):1171-5. PMC: 4701208. DOI: 10.1002/pbc.25454. View